



July 10, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Revised Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 10, 2024 titled **“Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets

Ahmedabad, India, 10 July, 2024

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (USRLD: Entresto[®] tablets).

Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Sacubitril and Valsartan tablets had annual sales of USD 5,483 mn in the United States (IQVIA MAT May 2024).

The group now has 399 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 31st March 2024)*



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878